Genzyme Corporation; Grant support: Biogen, Novartis Treatment optimization in MS: Canadian MS Working Group updated recommendations.
The U.S. Food and Drug Administration (FDA) has approved a Genzyme drug for patients with relapsing forms of multiple sclerosis (MS), the company announced.
Currently marketed drugs Lemtrada (Genzyme) and Zenapax (Blogen Idec/Abbott) will both expand into MS with a focus on relapsing-remitting MS.
(alemtuzumab) for the treatment of patients with relapsing remitting forms of multiple sclerosis (MS) to MS patients, said Genzyme President
by AA Miravalle 2024Sanofi Genzyme. He has received honoraria or speaker fees from Alexion Biogen, Genzyme and the National MS Society. ADB: Member of research
Read about Sanofi Genzyme presenting novel data on multiple sclerosis (MS) treatments Lemtrada and Aubagio at AAN 2024 in Boston. New Data on MS Drugs Lemtrada, Aubagio Presented by Sanofi Genzyme
MS and evaluate its potential as an effective MS treatment. Genzyme is developing vatelizumab in MS in partnership with Glenmark Pharmaceuticals
multiple sclerosis (MS) by Sanofi Genzyme. It was approved by the US Food and Drug Administration (FDA) in September 2024 for the treatment
MS treatment Lemtrada (Alemtuzumab), produced by Genzyme is listed for consideration by the Pharmaceutical Benefits Advisory Committee at their upcoming
Comments
Always a living fan,
Santacruzman